Skip to main content

Atopic Dermatitis

Featured Article
A 35-year-old man with severe erythrodermic atopic dermatitis experienced clearance of his disease after 4 months of adding rescue tofacitinib to dupilumab therapy, according to a recent case report.
“Publications have shown the positive effect of therapeutic patient education on the course of the disease, the prevention of complications, and the autonomy and quality of patient life,” researchers…

Insights

Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients, and…

Interactive Features

Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying patient…
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues sought to…
Back to Top